Sun Pharma Advanced Research Company
SPARCNSE

Sun Pharma Advanced Research Company

₹140.000.30 (0.21%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
139.32
Today’s high
145.01
52 week low
108.00
52 week high
204.40
Open price
139.95
Previous close
139.70
Live volume
31,59,657
Lower circuit
112.00
Upper circuit
168.00

Fundamentals

Market Cap
₹4,537Cr
ROE
77.47%
P/E Ratio(TTM)
-17.50
EPS(TTM)
-8.26
P/B Ratio
0.00
Dividend Yield
0.00%
Industry P/E
33.38
Book Value
-10.62
Debt to Equity
-1.21
Face Value
1

Financial performance

Quarterly
Yearly
All Financials
DEC '25
Revenue (Cr)
₹8.45
+7.37%
Profit (Cr)
-₹80.42
-6.03%
-100-62.5-25037.5
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25

About

Sun Pharma Advanced Research Company (SPARC) is a clinical-stage bio-pharmaceutical company focusing on research and development of innovative therapeutics.;
CEO/MD
Anil Raghavan
Founded in
2006
NSE symbol
SPARC

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
65.67%
Retail And Others
31.41%
Foreign Institutions
2.04%
Mutual Funds
0.85%
Other Domestic Institutions
0.03%

Mutual Funds Invested (1)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Innova CaptabINNOVACAP
₹871.05
+26.65 (3.16%)
L
    H
    4,840.6636.564.74
    ₹382.75
    +10.45 (2.81%)
    L
      H
      4,063.8684.9515.37
      ₹402.80
      -3.35 (0.82%)
      L
        H
        3,796.1942.365.2
        Aarti DrugsAARTIDRUGS
        ₹391.35
        -4.50 (1.14%)
        L
          H
          3,604.2517.82.45
          Livesquawk
          Sun Pharma's Seizaby, a neonatal seizure therapy, gets U.S. FDA PRV approval. Approval enhances treatment options for neonatal seizures by Sun Pharma.
          Livesquawk
          Sun Pharma Advanced Research to sell US priority review voucher for $195M. Transaction aims to boost pipeline development and strengthen innovation strategy.
          Livesquawk
          SPARC posts Q3 net loss of 806M rupees vs 797M YoY. Revenue declines to 85M rupees from 149M YoY.
          2026
          9
          Feb
          Quarterly Result
          Release date
          2025
          10
          Nov
          Quarterly Result
          Release date
          4
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks